Eagle Pharmaceuticals,Inc. (NYSE:TEVA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 – Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

Appointment of New Chief Financial Officer, Principal
Financial Officer and Principal Accounting Officer

On May15, 2017, Eagle Pharmaceuticals,Inc., or the Company,
announced that Pete A. Meyers would be joining the Company as its
Chief Financial Officer, effective May15, 2017. At a meeting of
the Board of Directors, or the Board, of the Company held on
May9, 2017, the Board approved the appointment of Mr.Meyers as
the Companys Chief Financial Officer and as the Companys
principal financial officer and principal accounting officer for
purposes of the Securities Exchange Act of 1934, as amended, or
the Exchange Act, in each case effective May15, 2017. David E.
Riggs will no longer serve as the Companys principal financial
officer or principal accounting officer, in each case effective
May15, 2017, but will remain with the Company and will assist
with the transition.

Mr.Meyers, age 47, most recently served as the Chief Financial
Officer of Motif BioSciences Inc. (NASDAQ: MTFB; AIM: MTFB) from
April2016 to January2017, where he led the execution of the
companys November2016 U.S. IPO. From August2013 to March2016,
Mr.Meyers served as Chief Financial Officer and Treasurer of
TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG), where he
led the execution of the companys December2013 IPO and subsequent
acquisition of Shape Pharmaceuticals,Inc. Prior to his role at
TetraLogic, Mr.Meyers spent 18 years in health care investment
banking, holding positions of increasing responsibility at
Dillon, ReadCo., Credit Suisse First Boston LLC and, most
recently, as Co-Head of Global Health Care Investment Banking at
Deutsche Bank Securities Inc. Mr.Meyers currently serves on the
Board of Directors of Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR),
where he chairs the audit committee. Mr.Meyers is also the
Chairman and President of The Thomas M. Brennan Memorial
Foundation,Inc. He earned a Bachelor of Science degree in Finance
from Boston College and a Master of Business Administration
degree from Columbia Business School.

In connection with his appointment, the Company entered into an
offer letter with Mr.Meyers, or the Offer Letter, under which
Mr.Meyers will receive an initial annual base salary of $400,000
and will be eligible to receive an annual cash performance bonus.
The target amount for Mr.Meyers 2017 cash performance bonus will
be equal to 60% of Mr.Meyerss base salary, with the actual bonus
amount to be determined by the Compensation Committee. The Offer
Letter does not provide for a specified term of employment and
Mr.Meyers employment is on an at-will basis. Mr.Meyers is also
eligible to participate in the Companys employee benefit,
retirement, severance and other plans, as may be maintained by
the Company from time to time, on a basis no less favorable than
those provided to other similarly-situated executives of the
Company.

In addition, and to the terms of the Offer Letter, the
Compensation Committee approved a grant to Mr.Meyers of an option
to purchase 50,000 shares of the Companys common stock, with a
grant date of May15, 2017 and an exercise price equal to the
closing price of the Companys common stock on the grant date.
Twenty-five percent (25%) of the shares underlying the option
vest on the on the one year anniversary of the grant date, and
the remainder of the shares underlying the option vest in 36
equal monthly installments thereafter, subject to Mr.Meyers
continuous service with the Company through each vesting date. In
addition, one hundred percent (50%) of the shares subject to the
option will vest in full in certain circumstances following a
change in control, in accordance with the terms of the Companys
form executive officer option award agreement.

The foregoing description of the Offer Letter is qualified in its
entirety by reference to the full text of the Offer Letter, which
is filed as Exhibit10.1 to this Current Report on Form8-K, and is
incorporated by reference herein.

Mr.Meyers will also enter into (i)an agreement to participate in
the Companys Severance Plan (as defined and described in the
Companys Proxy Statement filed with the SEC on April28, 2017),
(ii)the Companys standard form of indemnification agreement and
(iii)the Companys standard form of proprietary information,
invention assignment, non-competition and non-solicitation
agreement. Mr.Meyers was not appointed to serve as Chief
Financial Officer, principal financial officer and principal
accounting officer to any arrangements or understandings with the
Company (other than as reflected in the Offer Letter) or with any
other person, and there are no related party transactions between
Mr.Meyers and the Company that would require disclosure under
Item 404(a)of Regulation S-K.

Item 7.01 Regulation FD
Disclosure.

On May15, 2017, the Company issued a press release announcing the
appointment of Mr.Meyers as the Companys Chief Financial Officer
and the Companys principal financial officer and principal
accounting officer. A copy of the Companys press release is
furnished with this Current Report on Form8-K and attached hereto
as Exhibit99.1.

About Eagle Pharmaceuticals, Inc. (NYSE:TEVA)

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women’s health and selected other areas.

Eagle Pharmaceuticals, Inc. (NYSE:TEVA) Recent Trading Information

Eagle Pharmaceuticals, Inc. (NYSE:TEVA) closed its last trading session down -0.11 at 31.89 with 7,685,821 shares trading hands.